Compact, affordable flow cytometer allows scientists to conduct complex cell analyses at their benchtops

BILLERICA, Mass.–Millipore Corporation (NYSE: MIL), a leading provider of technologies, tools and services for the global life science industry, today announced the launch of the new guava easyCyte™ 8HT flow cytometry system. This compact, affordable, six-color detection system with 96-well automation allows scientists to move their research out of the core lab into their own lab. It is the first instrument introduced by Millipore since its acquisition of Guava Technologies, a leading provider of benchtop flow cytometers, earlier this year.

“Working with leading experts in the field of flow cytometry, we have designed an instrument with a revolutionary software interface and analytical capability; high-throughput 96 well compatibility; reduced reagent costs; and six-color capability—all within a small and affordable package,” said Geoffrey Crouse, Vice President of Millipore’s Life Sciences Business Unit. “We further enhance the ease of use to our customers by providing in-field service and ready-to-use reagents.”

The guava easyCyte 8HT six-color detection enables researchers to carry out highly multiplexed experiments in which six targets and eight parameters can be simultaneously analyzed in a single sample of cells. In addition to allowing researchers to analyze more targets, the six-color detection range also gives researchers greater freedom to choose fluorescent dyes with well separated emission spectra, which reduces the chance of overlap in the resulting signals and improves data quality.

“Flow cytometry is a critical component of our measurement toolbox. The guava flow cytometer is particularly key as it has made it possible to conduct cutting-edge research in my laboratory more efficiently and conveniently than ever before,” said Brian K. McFarlin, PhD, Associate Professor Exercise Physiology, Nutrition, and Immunology, Lab of Integrated Physiology, at the University of Houston. “Traditional flow cytometers need a full-time technician, making them expensive to operate, but guava flow cytometers only require the individual who will run the samples. In fact, in the last two years, we have run over 30,000 samples through the machine with absolutely no problems.

“The guava system has also allowed me to label blood samples that are 20 times smaller than those used from traditional flow cytometry,” continued Dr. McFarlin. “Not only does this lower required sample volume, but it also substantially reduces antibody and reagent expenses. I estimate that I have saved at least $60,000 in antibody and reagent costs over the past two years.”

As with all Guava flow cytometry systems, the easyCyte 8HT system utilizes patented microcapillary technology that reduces the number of cells needed for analysis and the amount of waste generated – from liters per day with traditional approaches to less than 50 mL per day. Elimination of complicated fluidics gives the instrument a small footprint and dramatically decreases user maintenance.

The easyCyte 8HT also features the new InCyte software package that significantly improves data analysis. InCyte software allows researchers to view, compare and analyze up to eight data sets simultaneously, which means that entire plates of data can be analyzed in less time than it typically takes to analyze data from a single sample using traditional software.

In addition to the new instrument, Millipore will be providing researchers with a total workflow solution that will include optimized reagent kits for life science and clinical applications, as well as in-field service.

Additional Resources

New Benchtop Flow Cytometry Podcast: https://www.millipore.com/guavapodcast

easyCyte system information page: https://www.millipore.com/guavarelease

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER™

Research. Development. Production

Safe Harbor Statement

Certain of the matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore’s future operating results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug or vaccine; delay, suspension or termination of a customer’s volume production; fluctuations in the timing of customers’ orders; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; risks relating to our concentration of principal manufacturing operations; the inability to successfully integrate acquired businesses; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

Millipore and Guava are registered trademarks and the “M” logo, easyCyte, and Advancing Life Science Together are trademarks of Millipore Corporation.

Photos/Multimedia Gallery Available: https://www.businesswire.com/cgi-bin/mmg.cgi?eid=6001060&lang=en